Stocks
Versartis, Inc.VSAR
NASDAQHealthcareBiotechnology$1.19-2.52%
A clinical-stage biotechnology company that focused on developing long‑acting protein therapeutics for endocrine disorders, most notably treatments targeting growth hormone deficiency. The company’s lead program, somavaratan (VRS‑317), advanced through late‑stage clinical trials before setbacks resh...
Market Cap: $052W Range: $1.14 – $2.75
Congressional Interest in Versartis, Inc. (VSAR)
1 member of Congress has disclosed 1 trade in Versartis, Inc. (VSAR), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading VSAR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-03-22 | BOB GIBBS | buy | $1K – $15K |